Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer (NCT04420754)
A Multicenter Phase I Study of AIC100 CAR T Cells in Relapsed and/or Refractory Advanced Thyroid Cancer or Anaplastic Thyroid Cancer
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to assess the safety and tolerability and determine the recommended Phase 2 dose of AIC100 Chimeric Antigen Receptor (CAR) T cells in patients with relapsed/refractory poorly differentiated thyroid cancer and anaplastic thyroid cancer, including newly diagnosed.
Who can join: Review the eligibility criteria below.
Location: City of Hope National Medical Center, City of Hope Medical Center — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (4 Sites)
- City of Hope National Medical Center, City of Hope Medical Center — Duarte, California
- Northwestern Memorial Hospital — Chicago, Illinois
- Weill Cornell Medical College — New York, New York
- MD Anderson Cancer Center — Houston, Texas
📞 Contact the Study Coordinator
Phone: (800) 826-4673
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Anaplastic Thyroid Cancer
- Trametinib in Combination With Paclitaxel in the Treatment of Anaplastic Thyroid Cancer — Basking Ridge, New Jersey
- Study of Cemiplimab Combined With Dabrafenib and Trametinib in People With Anaplastic Thyroid Cancer — Basking Ridge, New Jersey
- Zanzalintinib Plus Cemiplimab for the Treatment of BRAF Wild-Type Anaplastic Thyroid Cancer — Houston, Texas
- XL092 and Cemiplimab in BRAF WT Thyroid Cancer — Boston, Massachusetts
Explore by condition: All Anaplastic Thyroid Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.